Efficacy and safety of FIREHAWK® abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: Nine-month angiographic and one-year clinical results from TARGET I trial long cohort

Chinese Medical Journal

Volumn 126, Issue 6, 2013, Pages 1026-1032

  Xu, Bo ^a   Gao, Run Lin ^a   Zhang, Rui Yan ^b   Wang, Hai Chang ^c   Li, Zhan Quan ^d   Yang, Yue Jin ^a   Ma, Chang Sheng ^e   Han, Ya Ling ^f   Lansky, Alexandra J ^g   Huo, Yong ⁱ   Li, Wei ^a   Leon, Martin B ^h  

^a FUWAI HOSPITAL   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d Liaoning Provincial Peoples' Hospital   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f SHENYANG NORTHERN HOSPITAL   (China)

^g YALE NEW HAVEN HOSPITAL   (United States)

^h PEKING UNIVERSITY FIRST HOSPITAL   (China)

ⁱ Department of Medicine   (United States)

Author keywords

Biodegradable; Coronary artery disease; Drug eluting stents; Sirolimus

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RAPAMYCIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DEVICE SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; REVASCULARIZATION; STENT THROMBOSIS;

AGED; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 84876932931     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123206     Document Type: Article

References (26)

1. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza J P, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40: 2082-2089.
2. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. New Engl J Med 2006; 354: 483-495.
3. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: 583-591.
4. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005; 294: 819-825.
5. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. New Engl J Med 2005; 353: 653-662.
6. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. New Engl J Med 2005; 353: 663-670.
7. Lee CW, Park DW, Lee BK, Kim YH, Hong MK, Kim JJ, et al. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. Am J Cardiol 2006; 97: 506-511.
8. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, et al. Predictive factors of restenosis after coronary implantation of sirohmus- or paclitaxel-eluting stents. Circulation 2006; 113: 2293-2300.
9. Kobayashi Y, De Gregono J, Kobayashi N, Akiyama T, Reimers B, Finci L, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34: 651-659.
10. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol 1999; 83: 1617-1622.
11. Qian J, Xu B, Lansky AJ, Yang YJ, Qiao SB, Wu YJ, et al. First report of a novel ablummal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial. Chin Med J 2012; 125: 970-976.
12. Applegate R, Hermiller J, Williams J, Gordon P, Doostzadeh J, Cao S, et al. Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv 2010; 76: 644-651.
13. Popma JJ, Maun L, O'Shaughnessy C, Overlie P, McLaurin B, Almonacid A, et al. Frequency and clinical consequences associated with sidebranch occlusion during stent implantation using zotarolimus-eluting and paclitaxel-eluting coronary stents. Circ Cardiovasc Interv 2009; 2: 133-139.
14. Sheiban I, Villata G, Bollati M, Sillano D, Lotrionte M, Biondi-Zoccai G Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag 2008; 4: 31-38.
15. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial. Circulation 2005; 112: 3306-3313.
16. Yamawaki M, Muramatsu T, Araki M, Hirano K, Nakano M, Ishimori H, et al. Natural history of side branches jailed by drug-eluting stents. J Interv Cardiol 2012; 25: 37-46.
17. Xie H, Fang Q, Zhang S, Shen Z, Zeng Y, Wang C, et al. Side branch occlusion rate at sites of overlapping sirolimus-or paclitaxel-eluting stents for treating long coronary lesions. Chin J Cardiol (Chin) 2008; 36: 497.
18. Lansky AJ, Yaqub M, Hermiller JB, Smith RS, Farhat N, Caputo R, et al. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroInterv 2010; 6 Suppl J: J44-J52.
19. Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, et al. Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. JACC Cardiovasc Interv 2011; 4: 1096-1103.
20. Li Y Li CX, Wang HC, Xu B, Fang WY, Ge JB, et al. Efficacy and safety of Firebird sirolimus-elutmg stent m treatment of complex coronary lesions in Chmese patients: one-year clinical and eight-month angiographic outcomes from the FIREMAN registry. Chin Med J 2011; 124: 817-824.
21. Xu B, Dou KF, Han YL, Lu SZ, Yang YJ, Huo Y, et al. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-elutmg stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results. Chin Med J 2011; 124: 811-816.
22. Qiao SB, Hou Q, Xu B, Yang YJ, Chen JL, Gao RL. The clinical efficacy of sirolimus-eluting stents versus paclitaxel-eluting stents in complex and diffuse coronary lesions. Chin J Intern Med (Chin) 2006; 45: 985-987.
23. Xiang D, Yi S, Ruan Y, Gong Z, Hong C, Qiu J. Comparison of angiographic and IVUS follow-up between the two different drug-eluting stents implanted simultaneously in the same individuals. J Invasive Cardiol 2012; 24: 374.
24. Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, et al. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation 2011; 124: 624-632.
25. Kim U, Lee SH, Hong GR, Park JS, Shin DG, Kim YJ, et al. Two-year clinical outcomes of patients with long segments drug-elutmg stents: comparison of sirolimus-eluting stent with paclitaxel-eluting stent. J Korean Med Sci 2011; 26: 1299-1304.
26. Park SW, Lee SW, Koo BK, Park DW, Kim YH, Lee CW, et al. Treatment of diffuse m-stent restenosis with drug-eluting stents vs. intracoronary beta-radiation therapy: INDEED Study. Int J Cardiol 2008; 131: 70-77.